Akorn Recalls Eye Itch Relief Eye Drops Due to Manufacturing Deviations
Akorn, Inc. is voluntarily recalling 25,843 bottles of Eye Itch Relief eye drops due to CGMP deviations. The product was distributed nationwide in 14 states.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a remote possibility of temporary or medically reversible health consequences. The source text does not report any illnesses or injuries, and the hazard is related to manufacturing deviations rather than a specific high-risk pathogen or structural defect.
Plain-English summary
Akorn, Inc. is voluntarily recalling 25,843 bottles of Eye Itch Relief, Ketotifen Fumarate Ophthalmic Solution 0.035%, Sterile, 5 mL. The recall was initiated on September 3, 2020, and was classified as Class II by the FDA. The reason for the recall is Current Good Manufacturing Practice (CGMP) deviations.
The affected product is identified by Lot 8A11A with an expiration date of 12/20. It was distributed by CVS Pharmacy, Inc. in Woonsocket, RI, and is identified by NDC 59779-920-01. The product was distributed nationwide in California, Indiana, Virginia, New Jersey, New York, Rhode Island, Florida, Texas, Missouri, Pennsylvania, Michigan, Alabama, Tennessee, and South Carolina.
Consumers who have this product should stop using it and contact their healthcare provider or the recalling firm for further instructions. The recall was terminated on August 1, 2022.
The recalled product
- Product
- Eye Itch Relief, Ketotifen Fumarate Ophthalmic Solution 0.035%, Sterile, 5 mL, Distributed by CVS Pharmacy, Inc. Woonsocket, RI 02895, NDC 59779-920-01
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic Solution
- Hazard
- Affected units
- 25,843
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot 8A11A exp 12/20
Distribution
Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviations
See all →- SevereBaxter Recalls Famotidine Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateBaxter Recalls Pantoprazole Sodium Infusion Bags Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Nexterone Amiodarone Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Dexmedetomidine Hydrochloride Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- HighKetotifen Fumarate eye drops recalled due to manufacturing quality control deviations
FDA (Drugs) · 2023-05-24
- ModerateAkorn recalls Levofloxacin eye drops due to manufacturing compliance issues
FDA (Drugs) · 2023-01-25
- ModerateAkorn Ketorolac Eye Drops Recalled Due to Manufacturing Quality Deviations
FDA (Drugs) · 2023-06-07
- ModerateAkorn Recalls Moxifloxacin Ophthalmic Solution for CGMP Deviations
FDA (Drugs) · 2023-01-25
- HighPrescription Eye Drops Recalled for Manufacturing Control Deviations
FDA (Drugs) · 2023-01-25
- ModerateAkorn Artificial Tears Eye Drops Recalled for Manufacturing Quality Deviations
FDA (Drugs) · 2023-01-25